ChromaDex

ChromaDex is a bioscience company specializing in nicotinamide adenine dinucleotide (NAD+) technology for healthy aging applications. The company's flagship ingredient is NIAGEN, a patented form of nicotinamide riboside (NR) that serves as an NAD+ precursor. NIAGEN is the first and only FDA-approved form of NR, proven through multiple clinical trials to safely and effectively boost NAD+ levels in humans. The company also produces IMMULINA, a spirulina extract containing Braun-type lipoproteins for immune function support, and AnthOrigin, an anthocyanin ingredient derived from water-extracted purple corn. ChromaDex operates a reference standards and services business that provides natural products, phytochemical and botanical reference materials used by food companies, supplement firms, and testing laboratories to verify product quality. The company conducts extensive quality testing on all its products, with 22 different tests performed on each batch of NIAGEN and TRU NIAGEN supplements. Its laboratories are ISO/IEC 17025:2017 accredited. ChromaDex was acquired by International Flavors & Fragrances (IFF) in February 2021 as part of IFF's USD 26.2 billion merger with DuPont's Nutrition & Biosciences division.

Key customers and partnerships

ChromaDex established several strategic partnerships to expand its global reach. In September 2021, the company partnered with Sinopharm Xingsha Pharmaceuticals to facilitate cross-border sales of TRU NIAGEN in mainland China. ChromaDex entered into a strategic supply agreement with healthcare technology company Ro for exclusive access to NIAGEN for Roman products. The company also formed a licensing and supply partnership with Nestlé Health Science in 2018, granting them exclusive rights to use TRU NIAGEN in medical nutrition products across North America, Europe, Latin America, Australia, Japan, and New Zealand. ChromaDex expanded into the Singapore market in January 2018 through a retail partnership with Watsons, which began offering TRU NIAGEN in stores and online.